Jihui Hao, Executive Vice President of the China Anti-Cancer Association (CACA), President of Tianjin Medical University, and President of Tianjin Medical University Cancer Institute & Hospital, has been named a candidate for the Union for International Cancer Control (UICC) Board of Directors for the 2026–2028 term. UICC
Prof. Hao is among 24 candidates running for 14 seats on the UICC Board. UICC full-member organisations will elect the new Board during the 2026 UICC General Assembly, which will take place virtually on October 20, 2026. UICC
Electronic voting will open on October 13, 2026, and close during the General Assembly on October 20.
Jihui Hao’s Leadership in Oncology
Based in Tianjin, China, Prof. Hao is a cancer leader and oncologist whose work spans clinical care, research, education, and the management of cancer institutions.
He serves as Executive Vice President of CACA and President of Tianjin Medical University and its Cancer Institute & Hospital. His academic interests include pancreatic cancer, gastrointestinal malignancies, and precision oncology.
Prof. Hao has published extensively in high-impact scientific journals and has received State Science and Technology Awards for his contributions to cancer research and clinical translation.
He also serves as Chairman of the Cancer Precision Treatment Committee of CACA and Executive Editor-in-Chief of Cancer Biology & Medicine and the Chinese Journal of Clinical Oncology, contributing to the development and dissemination of oncology research and clinical knowledge.
Why Jihui Hao Is Running for the UICC Board
In his candidate statement, Prof. Hao highlighted his experience with CACA and his interest in strengthening connections between China’s cancer research and clinical networks and the international cancer community.
“I seek to join the UICC Board to bridge China’s vast clinical and research network with global strategies, fostering international collaboration in precision oncology, cancer centre management, and access to innovation.”
He said his experience in institutional governance, translational research, and national guideline development could contribute to UICC’s global capacity-building efforts, particularly in low- and middle-income settings.
Prof. Hao also identified strengthening cancer institutions and health systems as key areas where he hopes to contribute.
“My goal is to cultivate global-minded medical talents, and contribute to human health.”
Through CACA, he has also participated in international symposia and shared clinical data initiatives, providing opportunities for collaboration between Chinese oncology institutions and international partners.
Strengthening Cancer Institutions and Health Systems
Prof. Hao’s candidacy brings a focus on cancer centre management, quality control, workforce development, and the translation of research into clinical practice.
As President of Tianjin Medical University Cancer Institute & Hospital, he oversees a major comprehensive cancer institution and has experience across research, clinical care, education, and institutional leadership.
He said his experience could help UICC develop and share approaches to cancer centre management and workforce training internationally.
“I am eager to contribute to UICC’s priority area of strengthening health systems and cancer institutions.”
His proposed contribution also includes connecting institutional experience and scientific expertise with UICC’s broader global cancer-control priorities.
Precision Oncology and International Collaboration
Prof. Hao’s research background in pancreatic cancer, gastrointestinal malignancies, and precision oncology is another central component of his candidacy.
He highlighted the importance of international research collaboration and access to innovation, particularly as precision medicine continues to develop across cancer types.
His academic work has included publications in journals such as Cancer Cell, Gut, Gastroenterology, Nature Communications, and Science Advances, while his leadership at Tianjin Medical University Cancer Institute & Hospital has involved multi-centre research and evidence generation.
Prof. Hao also serves as Vice Director of the National Clinical Research Cancer Centre, giving him experience in coordinating clinical research and translating evidence into practice.
Bringing Chinese Oncology Experience to UICC
Prof. Hao said his experience at the intersection of clinical leadership, research, and national cancer policy would allow him to contribute to UICC’s international work.
“I am qualified to help UICC advance precision oncology, strengthen cancer institutions globally, and foster equitable research partnerships—bringing both Chinese institutional leadership and global scientific perspective to the Board.”
His candidacy comes as UICC seeks to bring together cancer organisations and professionals from different regions to strengthen global cancer control and facilitate knowledge exchange. UICC states that its 24 Board candidates represent diverse regions and backgrounds. UICC
Watch Prof. Jihui Hao’s video message outlining his experience, priorities, and vision as a candidate for the UICC Board of Directors for the 2026–2028 term.
UICC Board Elections 2026
The 2026 UICC election will determine 14 members of the Board of Directors for the 2026–2028 term.
UICC full-member organisations will vote during the virtual General Assembly on October 20, 2026. The 24 shortlisted Board candidates were selected from 51 nominations received by the UICC Nominating Committee. UICC
UICC notes that candidate profiles and views are provided by the candidates themselves to inform members participating in the election.
Read further on OncoDaily: Kathleen Schmeler Named Candidate for UICC Board of Directors 2026–2028
